Cps Technologies Corp. shares rise 1.81% after-hours following I-Mab's investment expansion and executive appointments.

Cps Technologies Corp. rose 1.81% in after-hours trading, with I-Mab announcing an acceleration of its investment in givastomig for metastatic gastric cancers. The company plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy in Q1 2026, with additional Phase 1b cohorts to follow. I-Mab also reiterated its expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026 and plans to broaden its 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC). Additionally, Mr. Wei Fu, I-Mab’s Chairman of the Board of Directors, was appointed as Executive Chairman, supported by further executive additions.